Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

被引：12

作者：

Kahraman, Seda ^{[1
]}

Erul, Enes ^{[2
]}

Seyyar, Mustafa ^{[3
]}

Gumusay, Ozge ^{[4
]}

Bayram, Ertugrul ^{[5
]}

Demirel, Burcin Cakan ^{[6
]}

Acar, Omer ^{[7
]}

Aksoy, Sercan ^{[2
]}

Baytemur, Naziyet Kose ^{[8
]}

Sahin, Elif ^{[3
]}

Cabuk, Devrim ^{[3
]}

Basaran, Gul ^{[4
]}

Paydas, Semra ^{[5
]}

Yaren, Arzu ^{[6
]}

Guven, Deniz Can ^{[2
]}

Erdogan, Atike Pinar ^{[7
]}

Demirci, Umut ^{[8
]}

Yasar, Alper ^{[9
]}

Bayoglu, Ibrahim Vedat ^{[9
]}

Hizal, Mutlu ^{[1
]}

Gulbagci, Burcu ^{[10
]}

Paksoy, Nail ^{[11
]}

Davarci, Sena Ece ^{[12
]}

Yilmaz, Funda ^{[13
]}

Dogan, Ozlem ^{[14
]}

Orhan, Sibel Oyucu ^{[15
]}

Kayikcioglu, Erkan ^{[16
]}

Aytac, Ali ^{[17
]}

Keskinkilic, Merve ^{[18
]}

Mocan, Eda Eylemer ^{[19
]}

Unal, Olcun Umit ^{[20
]}

Aydin, Esra ^{[21
]}

Yucel, Hakan ^{[22
]}

Isik, Deniz ^{[23
]}

Eren, Onder ^{[24
]}

Uluc, Basak Oyan ^{[4
]}

Ozcelik, Melike ^{[25
]}

Hacibekiroglu, Ilhan ^{[10
]}

Aydiner, Adnan ^{[11
]}

Demir, Hacer ^{[12
]}

Oksuzoglu, Berna ^{[13
]}

Cilbir, Ebru ^{[14
]}

Cubukcu, Erdem ^{[15
]}

Cetin, Bulent ^{[16
]}

Oktay, Esin ^{[17
]}

Erol, Cihan ^{[1
]}

Okutur, Sadi Kerem ^{[26
]}

Yildirim, Nilgun ^{[27
]}

Alkan, Ali ^{[28
]}

Selcukbiricik, Fatih ^{[29
]}

机构：

[1] Ankara Yildirim Beyazit Univ, Ankara City Hosp, Dept Med Oncol, TR-06800 Ankara, Turkiye

[2] Hacettepe Univ, Canc Inst, Dept Med Oncol, TR-06590 Ankara, Turkiye

[3] Kocaeli Univ, Med Fac Hosp, Dept Med Oncol, TR-41000 Kocaeli, Turkiye

[4] Acibadem Univ, Sch Med, Dept Med Oncol, TR-34750 Istanbul, Turkiye

[5] Cukurova Univ, Dept Med Oncol, TR-01330 Adana, Turkiye

[6] Pamukkale Univ Hosp, Dept Med Oncol, TR-20160 Denizli, Turkiye

[7] Manisa Celal Bayar Univ Hosp, Dept Med Oncol, TR-45120 Mersin, Turkiye

[8] Ankara Mem Hosp, Dept Med Oncol, TR-06520 Ankara, Turkiye

[9] Marmara Univ, Dept Med Oncol, Pendik Res & Applicat Hosp, TR-34899 Istanbul, Turkiye

[10] Sakarya Univ, Sch Med, Dept Med Oncol, TR-54187 Sakarya, Turkiye

[11] Istanbul Univ, Dept Med Oncol, TR-34093 Istanbul, Turkiye

[12] Afyonkarahisar Hlth Sci Univ, Dept Med Oncol, TR-03200 Afyonkarahisar, Turkiye

[13] Dr Abdurrahman Yurtaslan Ankara Oncol Training & R, Dept Med Oncol, TR-06200 Ankara, Turkiye

[14] Ankara Etlik City Hosp, Dept Med Oncol, TR-06170 Ankara, Turkiye

[15] Uludag Univ, Dept Med Oncol, TR-16059 Bursa, Turkiye

[16] Suleyman Demirel Univ, Dept Med Oncol, TR-32260 Isparta, Turkiye

[17] Aydin Adnan Menderes Univ, Dept Med Oncol, Training & Res Hosp, TR-09100 Aydin, Turkiye

[18] Dokuz Eylul Univ, Res & Applicat Hosp, Dept Med Oncol, TR-35340 Izmir, Turkiye

[19] Ankara Univ, Dept Med Oncol, TR-06080 Ankara, Turkiye

[20] Tepecik Training & Res Hosp, Dept Med Oncol, TR-35180 Izmir, Turkiye

[21] Recep Tayyip Erdogan Univ Training & Res Hosp, Dept Med Oncol, TR-53020 Rize, Turkiye

[22] Gaziantep Univ, Dept Med Oncol, TR-27580 Gaziantep, Turkiye

[23] Kocaeli Med Pk Hosp, Dept Med Oncol, TR-41140 Kocaeli, Turkiye

[24] Selcuk Univ, Dept Med Oncol, Med Fac Hosp, TR-42250 Konya, Turkiye

[25] Umraniye Training & Res Hosp, Dept Med Oncol, TR-34764 Istanbul, Turkiye

[26] Istanbul Arel Univ, Bahcelievler Mem Hosp, Dept Med Oncol, TR-34537 Istanbul, Turkiye

[27] Firat Univ Hosp, Dept Med Oncol, TR-23200 Elazig, Turkiye

[28] Mugla Sitki Kocman Univ Training & Res Hosp, Dept Med Oncol, TR-48000 Mugla, Turkiye

[29] Koc Univ Hosp, Dept Med Oncol, TR-34010 Istanbul, Turkiye

[30] Elazig Fethi Sekin City Hosp, Dept Med Oncol, TR-23280 Elazig, Turkiye

[31] Acibadem Bodrum Hosp, Dept Med Oncol, TR-48420 Mugla, Turkiye

[32] Canakkale Onsekiz Mart Univ, Dept Med Oncol, Res & Practice Hosp, TR-17100 Canakkale, Turkiye

[33] Adana City Training & Res Hosp, Dept Med Oncol, TR-01230 Adana, Turkiye

[34] Kocaeli Derince Training & Res Hosp, Dept Med Oncol, TR-41310 Kocaeli, Turkiye

[35] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, TR-46050 Kahramanmaras, Turkiye

[36] Necmettin Erbakan Univ, Dept Med Oncol, Meram Med Fac Hosp, TR-42080 Konya, Turkiye

[37] Gulhane Training & Res Hosp, Dept Med Oncol, TR-06010 Ankara, Turkiye

[38] Mersin City Hosp, Dept Med Oncol, TR-96015 Mersin, Turkiye

[39] Namik Kemal Univ, Dept Med Oncol, Hlth Applicat & Res Hosp, TR-59030 Tekirdag, Turkiye

[40] Van Yuzuncu Yil Univ, Dursun Odabas Hosp, Dept Med Oncol, TR-65090 Van, Turkiye

[41] Manisa City Hosp, Dept Med Oncol, TR-45040 Manisa, Turkiye

[42] Konya City Hosp, Dept Med Oncol, TR-42020 Konya, Turkiye

[43] Ordu State Hosp, Dept Med Oncol, TR-52200 Ordu, Turkiye

[44] Aydin Ataturk State Hosp, Dept Med Oncol, TR-09020 Aydin, Turkiye

[45] Izmir Bozyaka Training & Res Hosp, Dept Med Oncol, TR-35170 Izmir, Turkiye

[46] Anadolu Med Ctr, Dept Med Oncol, TR-34758 Istanbul, Turkiye

来源：

FUTURE ONCOLOGY | 2023年

关键词：

CDK; 4; 6; inhibitors; HER2-negative metastatic breast cancer; HR-positive; letrozole;

D O I：

10.2217/fon-2022-1287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

引用

页码：727 / 736

页数：10

共 19 条

[1] CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis [J].

Agostinetto, E. ;

Vian, L. ;

Caparica, R. ;

Bruzzone, M. ;

Ceppi, M. ;

Lambertini, M. ;

Ponde, N. ;

de Azambuja, E. .

ESMO OPEN, 2021, 6 (02)

[2] CDK 4/6 inhibitors for adjuvant therapy in early breast cancer-Do we have a clear winner? [J].

Akhade, Amol ;

Van Wambeke, Simon ;

Gyawali, Bishal .

ECANCERMEDICALSCIENCE, 2022, 16

[3] Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E [J].

Butt, AJ ;

McNeil, CM ;

Musgrove, EA ;

Sutherland, RL .

[4] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[5]

Finn RS, 2022, J CLIN ONCOL, V40

[6] Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1, TRIO-18) [J].

Finn, Richard S. ;

Boer, Katalin ;

Bondarenko, Igor ;

Patel, Ravindranath ;

Pinter, Tamas ;

Schmidt, Marcus ;

Shparyk, Yaroslav, V ;

Thummala, Anu ;

Voitko, Nataliia ;

Bananis, Eustratios ;

McRoy, Lynn ;

Wilner, Keith ;

Huang, Xin ;

Kim, Sindy ;

Slamon, Dennis J. ;

Ettl, Johannes .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) :419-428

[7] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[8] Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers [J].

Finn, Richard S. ;

Aleshin, Alexey ;

Slamon, Dennis J. .

BREAST CANCER RESEARCH, 2016, 18

[9] Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer [J].

Garcia-Trevijano Cabetas, M. ;

Lucena Martinez, P. ;

Jimenez Nacher, I. ;

Diaz Almiron, M. ;

Zamora Aunon, P. ;

Herrero Ambrosio, A. .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (04) :893-899

[10] CDK4/6 inhibitors in HR+/HER2-advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies [J].

Harbeck, Nadia ;

Bartlett, Meaghan ;

Spurden, Dean ;

Hooper, Becky ;

Zhan, Lin ;

Rosta, Emily ;

Cameron, Chris ;

Mitra, Debanjali ;

Zhou, Anna .

FUTURE ONCOLOGY, 2021, 17 (16) :2107-2122

← 1 2 →